MAPK7 and metastatic prostate carcinoma: In addtion, the identified interactions in metastatic prostate cancer contain several experimentally confirmed targets of hsa-miR-143 and −145, including CLINT1, CDKN1A, IRS1, MAPK7, PPM1D and SOD2.